Stock Price & Analysis

Based on the recent market data and analysis, MetLife (MET) stock shows mixed signals:

Technical Analysis:

• Current price at $81.22 shows weakness with RSI-14 at 37.24 indicating oversold conditions
• Trading below its 20-day SMA ($84.19) and approaching support at $80.14 (Fibonacci S2)
• MACD showing bearish momentum with -0.63 reading

Fundamental Factors:

• Strong analyst consensus with multiple "Buy" ratings
• Wells Fargo maintains $92 price target, representing 13.3% upside
• KBW maintains $100 price target, suggesting 23.1% potential upside

Recent Developments:

• Identified as a defensive stock in Evercore ISI's screen for trade war uncertainty
• Insider sentiment is negative with recent executive sales, including EVP & CRO selling 22,810 shares in December 2024

Conclusion: SELL

• Despite positive analyst ratings, technical indicators suggest continued downward pressure
• Current market conditions and insider selling signal potential further weakness
• Better to wait for technical indicators to show improvement before entering new positions

Based on the provided data and market analysis, here is the price prediction for MetLife (MET) stock in 2025:

MetLife stock is projected to reach $92-98 by end of 2025, driven by strong fundamentals and improving market conditions. The company's robust financial performance with expected revenue growth to $71.05B in 2024 and improving ROE of 14.71% supports this bullish outlook. Recent analyst ratings from Wells Fargo and KBW maintain "Buy" ratings with price targets of $92-100.

The S1 support level for MET Stock is $81.04 ,The R1 resistant level for MET Stock is $83.29.

As of the end of day on 2025-02-26, the price of MET Stock was $81.41.

The target price for MET Stock according to analyst rating is 98.10, with the highest price target at 108.00 and the lowest at 88.00. Analysts have a Strong Buy rating on MET Stock overall.

The market cap of MET is $56.0B.

Based on the financial data and recent analyst reports, here's a concise analysis of MetLife's valuation:

MetLife shows significant earnings deterioration with net income dropping from $5.1B in 2022 to $1.38B in 2023, indicating potential overvaluation concerns. The company's net margin declined sharply from 7.7% to 2.4% year-over-year, suggesting operational efficiency challenges. However, the debt-to-equity ratio improved from 131.56% to 122.27%, showing better financial leverage management.

Recent analyst coverage remains bullish, with Wells Fargo maintaining a Buy rating and $92 price target, while KBW reaffirmed their Buy rating with a $100 target. The consensus among analysts suggests a Strong Buy with an average price target of $98.18, representing a 15.51% upside potential from current levels.

The stock currently trades at $81.22, which appears fairly valued considering the deteriorating fundamentals but strong analyst support. The insider sentiment is notably negative, with recent insider selling activity including EVP & CRO MARLENE DEBEL's sale of 22,810 shares in December 2024.

MetLife, Inc. is a financial services company. The Company is engaged in providing insurance, annuities, employee benefits and asset management for individual and institutional customers. The Company operates through six segments: Group Benefits; Retirement and Income Solutions (RIS); Asia; Latin America; Europe, the Middle East and Africa (EMEA), and MetLife Holdings. Its Group Benefits segment offers life insurance, dental, group short- and long-term disability, individual disability, accidental death and dismemberment (AD&D) insurance, vision, and accident and health insurance, as well as prepaid legal plans and pet insurance. It also sells administrative services-only (ASO) arrangements to some employers. Its RIS segment provides funding and financing solutions that help institutional customers mitigate and manage liabilities primarily associated with their employee benefit programs using a spectrum of life and annuity-based insurance and investment products.

Based on the available data and market analysis, here is a projection for MetLife (MET) stock price in 2030:

MetLife stock is projected to reach approximately $145-155 by 2030, representing an 80-90% increase from current levels around $81. This forecast is driven by MetLife's strong market position in the insurance sector, consistent dividend growth (current yield 6.64%), and healthy valuation metrics with forward P/E of 13.78x suggesting room for multiple expansion.

The company's strategic focus on digital transformation and operational efficiency improvements, combined with its robust capital position and diversified revenue streams across insurance and investment management, positions it well for sustainable long-term growth through 2030.

MET has a total of 45000 employees.